This trial is studying the side effects and best dose of ribociclib when given with enzalutamide to see how well they work compared to enzalutamide alone in treating patients with prostate cancer.
2 Primary · 3 Secondary · Reporting Duration: Time of first dose until progression (25% increase in PSA from nadir) or death, assessed up to 2 years
90 Total Participants · 2 Treatment Groups
Primary Treatment: Ribociclib · No Placebo Group · Phase 1 & 2
Age 18+ · Male Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: